EML4-ALK translocations in lung cancer
The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.
1. A method for diagnosing a non-small cell lung cancer or susceptibility to non-small cell lung cancer in human subject comprising:
(a) performing a nucleic acid detection assay on a nucleic acid sample from a human subject to detect the presence of an EML4-ALK gene fusion in the nucleic acid sample, wherein the EML4-ALK gene fusion is (i) an E17;ins30A20 gene fusion between exon 17 of EML4 and intron 19 of ALK having a breakpoint region comprising SEQ ID NO: 1, or (ii) an E17ins30;ins65A20 gene fusion between exon 17 of EML4 and intron 19 of ALK having a breakpoint region comprising SEQ ID NO:2; and
(b) diagnosing the subject as having or being susceptible to non-small cell lung cancer based on the presence of the EML4-ALK gene fusion in the nucleic acid sample,
wherein the nucleic acid detection assay comprises amplification of a nucleic acid molecule with at least a primer pair, said primer pair comprising a forward primer comprising the nucleotide sequence set forth in SEQ ID NO: 19 and a reverse primer that hybridizes to exon 20 of ALK to produce amplified nucleic acid, and wherein the amplified nucleic acid comprises the sequence of SEQ ID NO: 1 or 2.
2. The method of claim 1 , wherein the sample is selected from the group consisting of: plasma, serum, and biopsy tissue.
3. The method of claim 2 , wherein the sample is a lung biopsy sample.
4. The method of claim 1 , wherein amplification of a nucleic acid comprises PCR or real time PCR (RT-PCR).
5. The method of claim 1 , wherein the amplification of a nucleic acid comprises reverse transcriptase PCR.
6. The method of claim 1 , wherein the forward and/or the reverse primer and detectable labeled.
7. The method of claim 1 , further comprising electrophoresis of the amplified nucleic acid.
8. The method of claim 1 , further comprising using a real-time PCR detection system.
9. The method of claim 1 , further comprising performing a nucleic acid detection assay on the nucleic acid sample to detect one or more additional EML4-ALK gene fusions selected from the group consisting of: variant 1, variant 2, variant 3a, variant 3b, variant 4, variant 5a, variant 5b, variant 6, and variant 7.
10. The method of claim 1 , wherein both E17;ins30A20 and E17ins30;ins65A20 gene fusions are detected.
11. The method of claim 1 , wherein the EML4-ALK gene fusion is Detected by sequencing the amplified nucleic acid.
12. The method of claim 1 , wherein the reverse primer comprises the Sequence set forth is SEQ ID NO: 25.
13. The method of claim 1 , wherein the EML4ALK gene fusion is detected by hybridizing a labeled oligonucleotide probe to the amplified nucleic acid.
14. A method for detecting an E17;ins30A20 or E17ins30;ins65A20 EML4-ALK gene fusion comprising amplifying a nucleic acid molecule with at least a primer pair, said primer pair comprising a forward primer that hybridizes to exon 17 of EML4 and a reverse primer that hybridizes to exon 20 of ALK to produce amplified nucleic acid, and detecting amplified nucleic acid comprising the sequence of SEQ ID NO: 1 or SEQ ID NO: 2, thereby detecting the E17;ins30A20 or E17ins30;ins65A20 EML4-ALK gene fusion, wherein detecting the amplified nucleic acid comprising the sequence of SEQ ID NO: 1 indicated the presence of the E17ins30;ins65A20 EML4-ALK gene fusion.
15. The method of claim 14 , wherein the E17;ins30A20 or E17ins30;ins65A20 EML4-ALK gene fusion is detected in a sample selected from the group consisting of: plasma, serum, and biopsy tissue.
16. The method of claim 14 , wherein the E17;ins30A20 or E17ins30;ins65A20 EML4-ALK gene fusion is detected in a lung biopsy sample.
17. The method of claim 14 , wherein the nucleic acid amplification comprises PCR or real time PCR (RT-PCR).
18. The method of claim 14 , wherein the nucleic acid amplification comprises reverse transcriptase PCR.
19. The method of claim 14 , wherein the forward and/or the reverse primer are detectably labeled.
20. The method of claim 14 , further comprising electrophoresis of the amplified nucleic acid.
21. The method of claim 14 , further comprising using real-time PCR detection system.
22. The method of claim 14 , wherein the forward primer comprises the nucleotide sequence set forth in SEQ ID NO: 19.
23. The method of claim 14 , wherein the reverse primer comprises the nucleotide sequence set forth in SEQ ID NO: 25.
24. The method of claim 14 , wherein the forward primer comprises the nucleotide sequence set forth in SEQ ID NO: 19 and the reverse primer comprises the nucleotide sequence set forth in SEQ ID NO: 25.
25. A method for detecting an E17;ins30A20 or an E17ins30;ins65A20 EML4-ALK gene fusion in a nucleic acid sample, comprising hybridizing an oligonucleotide probe to target nucleic acid in the nucleic acid sample to form a hybridization complex between the oligonucleotide probe and target nucleic acid wherein the oligonucleotide probe comprises the nucleotide sequence set forth in any of SEQ ID NOs: 26-28, or the complements thereof; and detecting the presence of hybridization complexes comprising target nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1 to thereby detect the presence of the E17;ins30A20 EML4-ALK gene fusion in the nucleic acid sample or detecting the presence of hybridization complexed comprising target nucleic acid comprising the nucleotide sequence of SEQ ID NO: 2 to the thereby detect the presence of the E17ins30;ins65A20 EML4ALK gene fusion in the nucleic acid sample.
26. The method of claim 25 , wherein the oligonucleotide probe is detectable labeled.